The scid mutation was backcrossed on to the NOD/Shi mouse background, resulting in the development of NOD/Shi-scid mice, which showed lack of mature lymphocytes, macrophage dysfunction and absence of circulating complement, but were not as impaired in natural killer (NK) cell activity as NOD/LtSz-scid mice. We then examined the effect of recipient NK cell depletion by anti-asialo GM1 antiserum on the repopulation of human cord blood (CB) hematopoietic stem cells ( HSC would allow a more rational approach to the development of clinical treatments including HSC transplantation, ex vivo HSC expansion and gene therapy. Until recently, however, in contrast to mouse in vivo assays using syngeneic recipients, 1,2 no comparable system has been established in humans. To address this issue, several strategies have been pursued to develop an animal recipient for human HSC. In sheep and dog models, intrauterine injection of human HSC has reproducibly resulted in long-term reconstitution of human hematopoiesis.
HSC would allow a more rational approach to the development of clinical treatments including HSC transplantation, ex vivo HSC expansion and gene therapy. Until recently, however, in contrast to mouse in vivo assays using syngeneic recipients, 1, 2 no comparable system has been established in humans. To address this issue, several strategies have been pursued to develop an animal recipient for human HSC. In sheep and dog models, intrauterine injection of human HSC has reproducibly resulted in long-term reconstitution of human hematopoiesis. 3, 4 Genetically immuno-deficient mice homozygous for the scid mutation lacking functional B and T cells are widely used for xenogeneic transplantation of human HSC. 5, 6 More recently, to develop a mouse stock with defective lymphoid function accompanied by reduced nonadaptive immunologic function, the scid mutation was backcrossed on to the nonobese diabetic (NOD/Lt) mouse background. In addition to lacking B and T cell function, the resulting NOD/LtSz-scid/scid (NOD/LtSz-scid) mice exhibit low natural killer (NK) cell activity, are defective in macrophage function, and lack circulating complement. 7 NOD/LtSz-scid mice have shown more efficient engraftment of human HSC than the scid mice. [8] [9] [10] [11] [12] We also backcrossed the scid mutation on to the NOD/Shi mouse background. [13] [14] [15] Interestingly, the phenotype of the NOD/Shi-scid mice differed to some extent from that of the NOD/LtSz-scid mice. Although NOD/Shiscid mice also lack mature lymphocytes, show macrophage dysfunction and lack circulating complement, the NK cell activity of the mice is not so impaired. 13 Then, we examined the effect of recipient NK cell depletion by anti-asialo GM1 antiserum treatment on human HSC engraftment in NOD/Shi-scid mice to clarify the role of recipient NK cells in human HSC transplantation. The result showed that the anti-asialo GM1 antiserum treatment significantly enhanced the engraftment of cord blood (CB) CD34
+ cells in NOD/Shi-scid mice. The present study has important implications for the design of preconditioning treatment in human HSC transplantation, and the developed mouse model may provide a useful preclinical tool for assaying human HSC.
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Materials and methods
Cell preparation
Human umbilical CB samples were obtained according to institutional guidlines from normal full-term deliveries. Mononuclear cells (MNC) were separated by Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation after depletion of phagocytes with Silica (Immuno Biological Laboratories, Fujioka, Japan).
Purification of CD34
+ cells
Human CB MNC were resuspended at 3 to 5 × 10 7 /ml in phosphate-buffered saline (PBS; Nissui, Tokyo, Japan) and mixed with Dynabeads M-450 CD34 (Dynal, Oslo, Norway), with a beads to cell ratio of 1:1. The cell-bead suspension was resuspended and incubated at 4°C for 30 min with gentle rotation. After incubation, the cell-bead suspension volume was expanded and placed in a Dynal Magnetic Particle Concentrator (MPC) to collect the Dynabeads M-450 CD34/rosetted cells. The rosetted cells were incubated with DETACHaBEAD CD34 (Dynal) at room temperature for 45 min to detach the Dynabeads M-450 CD34 from the positively selected cells. The released CD34 + cells were collected by placing the tube in MPC, and their purity was evaluated by flow cytometric analysis. Eighty-five to 95% of the cells separated were CD34-positive.
Animals
NOD/Shi-scid/scid and C.B.-17-scid/scid mice were housed under specific pathogen-free conditions in a laminar air flow unit and supplied with sterile food and drinking water. Mice received water containing prophylactic neomycin sulfate (Gibco BRL, Grand Island, NY, USA) after transplantation.
Transplantation of human CB CD34
+ cells into immunodeficient mice Eight-to 10-week-old mice were sublethally irradiated with 240 cGy as two divided doses by a 137 Cs source immediately before transplantation. In the preliminary experiments, we determined that 240 cGy was the maximum dose required for more than 90% survival of recipients treated with anti-asialo GM1 antiserum as mentioned below. The separated human CB CD34 + cells were resuspended in 0.5 ml of PBS containing 1% bovine serum albumin (BSA; Sigma, St Louis, MO, USA) for transplantation and were injected into recipient mice via a tail vein. The recipient mice were injected with 20 l of anti-asialo GM1 antiserum (Wako Pure Chemical Industries, Osaka, Japan) diluted with ␣-medium (Flow Laboratories, Rockville, MD, USA) at the designated day. Since it was reported that NK cell activity was markedly reduced on day 3 after the one-shot injection, began to recover on day 7, and rose to more than 50% of the original value on day 14, 16 the injection of antiasialo GM1 antiserum was performed on days 0, 11, 22, 33 and/or 44 of transplantation.
Flow cytometric analysis for human hematopoietic cell engraftment
Mice were killed 10 to 12 weeks after the transplantation, and bone marrow (BM) cells collected from femurs and tibias were suspended in ␣-medium. 
NK cell activity assay
NK cell activity was enhanced by the intraperitoneal injection to mice with polyinosinic-polycytidylic acid (Poly I: C, Sigma) 24 h before the assay. Anti-asialo GM1 antiserum (20 l) was injected into mice intraperitoneally 48 h before the assay.
51
Cr-labeled target cells, YAC-1, were incubated with mouse spleen cells as effector cells (target/effector ratio: 1:3.7, 1:11, 1:33 and 1:100). Supernatant was harvested and measured for radioactivity with a gamma counter after 4 h of incubation at 37°C. Percent specific release was calculated according to the following formula: % cytotoxity = 
Results
Effect of anti-asialo GM1 antiserum treatment on NK cell activity of NOD/Shi-scid and scid mice
We first examined the effects of anti-asialo GM1 antiserum treatment on the NK cell activity of NOD/Shi-scid and scid mice. The NK cell activity of NOD/Shi-scid mice was two thirds to a half of the activity of scid mice, although higher than that of NOD/LtSz-scid mice ( Figure 1 and data not shown). One-shot injection of 20 l of anti-asialo GM1 antiserum reduced to a similar level of NK cell activity in both mice.
Engraftment of CD34 + cells in NOD/Shi-scid mice untreated and treated with anti-asialo GM1 antiserum
We then compared the repopulation of CB CD34
+ cells between NOD/Shi-scid mice untreated and treated with anti-asialo GM1 antiserum every 11 days from day 0 to day 44 ( Figure 2 ). When 1 to 3 and 4 to 6 × 10 4 CD34
+ cells were transplanted into untreated NOD/Shi-scid mice, only one out of 12 (8%) and two out of five recipients (40%) were successfully engrafted, respectively. By contrast, 17 out of 24 (71%) and six out of eight recipients (75%) treated with anti-asialo GM1 antiserum exhibited successful engraftment when transplanted with 1 to 3 and 4 to 6 × 10 4 CD34 + cells, respectively. The proportion of human CD45
+ cells in BM was significantly higher in mice treated with anti-asialo GM1 antiserum than untreated mice (0.2 Ϯ 0.6 and 1.5 Ϯ 2.3% in untreated recipients and 9.1 + cells, respectively). The above result suggests that recipient NK cell depletion by anti-asialo GM1 antiserum enhances the engraftment of CB CD34
+ cells in NOD/Shi-scid mice. To confirm this, 4 × 10 4 CB CD34 + cells obtained from six different CB samples were transplanted into NOD/Shi-scid mice untreated and treated with anti-asialo GM1 antiserum every 11 days from day 0 to day 44. As shown in Figure  3 , CD34 + cells obtained from three samples engrafted in both untreated and treated mice, whereas those from three other samples engrafted in treated but not untreated mice.
The percentage of human CD45
+ cells in BM of the treated recipient 12 weeks after the transplantation was much higher than that of the untreated recipient in all of six samples. This result clearly demonstrated the enhancement of CB CD34
+ cell engraftment in NOD/Shi-scid mice by anti-asialo GM1 antiserum treatment.
Effect of anti-asialo GM1 antiserum treatment on the differentiation of CD34 + cells engrafted in NOD/Shi-scid mice
We further analyzed the expression of various lineage markers on human CD45
+ cells reconstituted by CD34 + cells from the same CB samples in BM of NOD/Shi-scid mice untreated and treated with anti-asialo GM1 antiserum. + cells from six CB samples were respectively transplanted into recipients untreated and treated with anti-asialoGM1 antiserum every 11 days from day 0 to day 44. there was no remarkable difference in the proportions of CD33 + /CD14 + /CD38 + myelocytes and CD34 + immature cells between the two mice ( Figure 4 ). CD19
+ B cells were also present at a similar level in human CD45
+ cells in BM of treated and untreated mice, and their stage of differentiation as assessed by staining with anti-human IgM and CD10 was similar (Figure 4 and data not shown). In both treated and untreated mice, neither CD3 + T cells nor CD56 + NK cells were detected. The same result was obtained in analyses using two other CB samples. These findings indicate that anti-asialo GM1 antiserum treatment enhances the engraftment of CB CD34 + cells in NOD/Shi-scid mice, but does not affect the differentiation of the engrafted HSC.
Timing of anti-asialo GM1 antiserum treatment
We examined at which stage the NK cell depletion is required for the efficient engraftment of CB CD34 + cells in NOD/Shi-scid mice. CD34 + cells (3 × 10 4 ) from the same CB sample were transplanted into NOD/Shi-scid mice uninjected, or injected with anti-asialo GM1 antiserum on days 0 and 11, days 22 and 33, or days 0, 11, 22, 33 and 44 (two mice each) ( Table 1) . No engraftment was achieved in untreated recipients, and the two mice treated on days 0, 11, 22, 33 and 44 were successfully engrafted, consistent with the above results. Interestingly, the two mice treated on days 0 and 11 showed successful engraftment, whereas no mice treated on days 22 and 33 could be engrafted. We Table 1 Effect of anti-asialo GM1 antiserum treatment on engraftment of human CB CD34 + cells in NOD/Shi-scid mice Figure 1 demonstrated that anti-asialo GM1 antiserum treatment reduced the NK cell activity of not only NOD/Shi-scid mice but also scid mice who show mature lymphocyte deficiency but neither impaired NK cell activity, macrophage dysfunction nor loss of circulating complement, we examined the effect of this treatment on the engraftment of CB CD34
+ cells in scid mice. CD34
) from the same CB sample were respectively transplanted into two NOD/Shi-scid and scid mice untreated or treated with anti-asialo GM1 antiserum (Table  2) . Although in all the NOD/Shi-scid mice the engraftment was successful, the proportions of human CD45 + cells were much higher in BM of treated than untreated mice. By contrast, there was no engraftment in scid mice including those treated with anti-asialo GM1 antiserum. This result indicates that recipient NK cell depletion in addition to mature lymphocyte deficiency is not sufficient for efficient engraftment of CB CD34 + cells.
Discussion
The role of recipient NK cells in HSC graft rejection has been studied in various transplantation systems including allogeneic and xenogeneic transplantation. 17, 18 Recently, a high level of success in human HSC engraftment was achieved in NOD/LtSz-scid mice with reduced NK cell activity. [7] [8] [9] [10] [11] [12] However, since the NOD/LtSz-scid mice possess various immunodeficiencies in addition to an impaired NK cell activity, it has been unclear to what extent recipient NK cells participate in the resistance to human HSC 
All the mice were transplanted with 4 × 10 4 CD34 + cells separated from the same human CB sample. Anti-asialo GM1 antiserum was injected every 11 days intraperitoneally from day 0 to day 44.
Bone Marrow Transplantation engraftment. In the present study, we demonstrated that the recipient NK cell depletion by anti-asialo GM1 antiserum significantly enhanced human CB HSC engraftment in NOD/Shi-scid mice, which are characterized by a lack of mature lymphocytes, macrophage dysfunction and absence of circulating complement, but a less impaired NK cell activity as compared with NOD/LtSz-scid mice. Although the exact mechanism of the inhibitory effect of recipient NK cells on the reconstitution of hematopoietic cells in the recipients remains unknown, NK cell depletion did not affect the differentiation of engrafted HSC into each hematopoietic lineage, and was ineffective 3 weeks after the transplantation. In particular, NK cell depletion on day 0 was sufficient for the engraftment of HSC in NOD/Shi-scid mice. Therefore, NK cells may act on the early development of transplanted HSC including homing to recipient hematopoietic environments.
Thus, the present study revealed a crucial role for recipient NK cells in HSC graft rejection. T cells have also been shown to be effector cells in HSC graft rejection. [19] [20] [21] However, we observed that the NK cell depletion did not enhance the engraftment of CB CD34
+ cells in scid mice who lack mature lymphocytes, but show neither macrophage dysfunction nor an absence of circulating complements, suggesting that macrophages and/or circulating complements play a role in HSC graft rejection. HSC graft rejection seems to be a consequence of a complex array of immunological reactions.
Aside from providing insight into the mechanisms behind HSC graft rejection, the present study has important implications for therapeutic HSC transplantation. One of the major obstacles to a successful transplantation is graft failure. In particular, the incidence of graft rejection is high for CB transplantation in patients with nonmalignant disorders. 22 The present results indicate that a strategy to specifically target recipient NK cells in addition to T cell suppression and myeloablation in the preconditioning may prevent the graft failure. In addition, the present study shows that xenotransplantation into NOD/Shi-scid mice treated with anti-asialo GM1 antiserum may be a useful tool comparable with the NOD/LtSz-scid mouse model for evaluating the repopulating ability of transplantable human HSC.
